Hasil Pencarian  ::  Simpan CSV :: Kembali

"This book clearly demonstrates the progression of nanoparticle therapeutics from basic research to applications. This book, unlike others covering nanoparticles used in medical applications, presents the medical challenges that can be reduced or even overcome by recent advances in nanoscale drug delivery. Each chapter highlights recent progress in the design and engineering of select multifunctional nanoparticles with topics covering targeting, imaging, delivery, diagnostics, and therapy."

"

Sistem penghantaran tertarget kolon dapat meningkatkan efek terapi pada pengobatan penyakit spesifik kolon, seperti Crohn’s disease, ulcerative colitis (UC) dan irritable bowel syndrome (IBS). Selain itu, kolon dapat menjadi lokasi yang sesuai untuk penghantaran obat yang rentan enzim saluran cerna, seperti peptida dan protein terapeutik. Dalam upaya untuk meningkatkan efek terapi, maka dikembangkan sistem penghantaran spesifik kolon menggunakan berbagai strategi dan pendekatan dengan mempertimbangkan kondisi fisiologis saluran cerna dan sifat fisikokimia obat. Review kali ini akan membahas mengenai faktor dan tantangan yang ditemui terkait pembuatan sistem penghantaran, serta strategi dan pendekatan yang dapat dilakukan dalam mengembangkan sistem penghantaran tertarget kolon ini.

---

Colon-specific drug delivery system (CDDS) are desirable to improve therapeutic effect for the treatment of local diseases such as Crohn’s disease, ulcerative colitis (UC) and irritable bowel syndrome (IBS). Colon also can be potential site for the delivery of several fragile molecules towards gastric pH such as peptide and protein therapeutic. In order to improve therapeutic effect, development of colon-targeted delivery system which consider several colon physiology condition and physicochemical drugs is needed. This review highlights several factors and challenges that influence colon-specific drug delivery, approaches and strategy for site specific drug delivery to colon.

"

"Written for busy professionals at the forefront of new drug development, "Drug delivery" gets readers quickly up to speed on both the principles and latest applications in the increasingly important field of drug delivery. Recent developments in such areas as combinatorial chemistry, proteomics, and genomics have revolutionized researchers' ability to rapidly identify and synthesize new pharmacological compounds. However, delivery-related properties remain a significant reason for clinical trial failures. It begins with an in-depth review of key fundamentals, such as physiochemical and biological barriers; drug delivery pathways; metabolism; drug formulation; pharmacokinetic and pharmacodynamic issues; and more. The remainder of the book is devoted to the systematic examination, including overviews, timely examples, and extensive references, of a host of specific subjects."

"Pirfenidon yang dihantarkan secara peroral mengalami metabolisme lintas pertama, sehingga memerlukan dosis tinggi dan berpotensi menyebabkan efek samping sistemik. Oleh karena itu, pengembangan rute alternatif bagi pirfenidon perlu dilakukan. Penelitian sebelumnya melaporkan bahwa sistem penghantaran intrapulmonal berbasis solid lipid nanoparticles (SLN) dapat terdeposit dengan baik pada area alveolus paru-paru. Namun, karakteristik SLN dapat dipengaruhi oleh rasio lipid terhadap obat, jenis dan konsentrasi polimer. Oleh karena itu, optimisasi dengan metode permukaan respon perlu dilakukan untuk memperoleh formula SLN pirfenidon (P-SLN) yang optimal untuk penghantaran intrapulmonal. Lima belas formula disusun berdasarkan desain Box Behnken dengan tiga faktor yaitu, rasio lipid terhadap obat, jenis polimer dan konsentrasi polimer, serta tiga respon, meliputi ukuran partikel, PDI dan efisiensi penjerapan. Formula P-SLN optimal dikarakterisasi meliputi morfologi, kadar lembab, performa aerodinamik, studi disolusi dan stabilitas. Hasil optimisasi menunjukkan bahwa P-SLN optimal tersusun dari rasio lipid terhadap obat 6:1 dan 0,5% Plasdone K-29/32 (FO1). P-SLN FO1 memiliki bentuk sferis dengan ukuran partikel 212,67 nm, PDI 0,39, efisiensi penjerapan 95,02%, dan kadar lembab 1,59%. FO1 memiliki mass median aerodynamic diameter berkisar antara 0,54–12,12 μm. Selain itu, FO1 melepaskan pirfenidon sebanyak 89,61% dan 69,28% dalam medium pH 4,5 dan pH 7,4 selama 45 menit. Sebagai kesimpulan, FO1 terbukti memiliki karakteristik yang sesuai untuk menghantarkan pirfenidon melalui rute intrapulmonal.

---

Orally administration of pirfenidone undergoes first-pass metabolism, hence requires high dose level and leads to systemic side effects. Therefore, it is necessary to develop an alternative route of administration for pirfenidone. Previous research reported that the solid lipid nanoparticle-based (SLN) intrapulmonary drug delivery system (IPDDS) was deposit well in the alveolar region of the lungs. However, the characteristics of SLN could be influenced by lipid-to-drug ratio, polymer type and concentration. Therefore, optimization using response surface methodology was carried out to obtain the optimized pirfenidon-loaded SLN (P-SLN) formula for IPDDS. Box-Behnken design was applied to create 15 formulas comprising three factors, including lipid-to-drug ratio, type and concentration of polymer and three responses, including particle size, PDI and entrapment efficiency. The optimized P-SLN formula was characterized, including morphology, moisture content, aerodynamic performance, dissolution and stability studies. The optimization results yielded an optimized P-SLN comprised a lipid-to-drug ratio of 6:1 and 0.5% Plasdone K-29/32 (FO1). The P-SLN FO1 had a spherical shape with a particle size of 212.67 nm, PDI of 0.39, entrapment efficiency of 95.02%, and moisture content of 1.59%. FO1 had a mass median aerodynamic diameter ranging from 0.54–12.12 μm. In addition, FO1 release 89.61% and 69.28% pirfenidone for 45 minutes in buffer medium pH 4.5 and pH 7.4. In conclusion, FO1 was proven to have an appropriate IPDDS characteristics for delivering pirfenidone."